Single nucleotide polymorphism (snp)-based loss of heterozygosity (loh) testing by real time pcr in patients suspect of myeloproliferative disease

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Huijsmans, Cornelis J J ^a   Poodt, Jeroen ^a   Damen, Jan ^a   van der Linden, Johannes C ^a   Savelkoul, Paul H M ^b   Pruijt, Johannes F M ^a   Hilbink, Mirrian ^a   Hermans, Mirjam H A ^a  

^a JEROEN BOSCH HOSPITAL   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; PHENYLALANINE; VALINE; JAK2 PROTEIN, HUMAN;

AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENE LOCATION; GENE LOCUS; GENETIC IDENTIFICATION; GERM LINE; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; JANUS KINASE 2 GENE; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; MYELOPROLIFERATIVE NEOPLASM; PREDICTION; PROCESS DEVELOPMENT; REAL TIME POLYMERASE CHAIN REACTION; RELIABILITY; SENSITIVITY AND SPECIFICITY; SHORT TANDEM REPEAT; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TUMOR GENE; ALLELE; AMINO ACID SUBSTITUTION; COHORT ANALYSIS; ENZYMOLOGY; GENETICS; METABOLISM; MISSENSE MUTATION; MYELOPROLIFERATIVE DISORDER; PATHOLOGY;

ALLELES; AMINO ACID SUBSTITUTION; COHORT STUDIES; FEMALE; HUMANS; JANUS KINASE 2; LOSS OF HETEROZYGOSITY; MALE; MUTATION, MISSENSE; MYELOPROLIFERATIVE DISORDERS; POLYMORPHISM, SINGLE NUCLEOTIDE; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84863611346     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038362     Document Type: Article

References (24)

1. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, et al. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365: 1054-1061.
2. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, et al. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434: 1144-1148.
3. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, et al. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352: 1779-1790.
4. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, et al. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7: 387-397.
5. Schindler C, Darnell JE Jr, (1995) Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem 64: 621-651.
6. Steensma DP, (2006) JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn 8: 397-411; quiz 526.
7. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, et al. (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114: 937-951.
8. Yamamoto G, Nannya Y, Kato M, Sanada M, Levine RL, et al. (2007) Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. Am J Hum Genet 81: 114-126.
9. Scott LM, Scott MA, Campbell PJ, Green AR, (2006) Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 108: 2435-2437.
10. Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, et al. (2007) Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 110: 840-846.
11. Passamonti F, Rumi E, (2009) Clinical relevance of JAK2 (V617F) mutant allele burden. Haematologica 94: 7-10.
12. Antonioli E, Guglielmelli P, Poli G, Bogani C, Pancrazzi A, et al. (2008) Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica 93: 41-48.
13. Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, et al. (2007) Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 21: 1952-1959.
14. Barosi G, Bergamaschi G, Marchetti M, Vannucchi AM, Guglielmelli P, et al. (2007) JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 110: 4030-4036.
15. Dupont S, Masse A, James C, Teyssandier I, Lecluse Y, et al. (2007) The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood 110: 1013-1021.
16. Larsen TS, Pallisgaard N, Moller MB, Hasselbalch HC, (2007) The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis-impact on disease phenotype. Eur J Haematol 79: 508-515.
17. Tefferi A, Lasho TL, Schwager SM, Strand JS, Elliott M, et al. (2006) The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer 106: 631-635.
18. Huijsmans CJ, Poodt J, Savelkoul PH, Hermans MH, (2011) Sensitive detection and quantification of the JAK2V617F allele by real-time PCR blocking wild-type amplification by using a peptide nucleic acid oligonucleotide. J Mol Diagn 13: 558-564.
19. Kissel HD, Galipeau PC, Li X, Reid BJ, (2009) Translation of an STR-based biomarker into a clinically compatible SNP-based platform for loss of heterozygosity. Cancer Biomark 5: 143-158.
20. Watling CJ, van Meyel DJ, Ramsay DA, Macdonald DR, Cairncross JG, (1995) Loss of heterozygosity analysis of chromosomes 9, 10 and 17 in gliomas in families. Can J Neurol Sci 22: 17-21.
21. Jen J, Kim H, Piantadosi S, Liu ZF, Levitt RC, et al. (1994) Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 331: 213-221.
22. Lanza G, Matteuzzi M, Gafa R, Orvieto E, Maestri I, et al. (1998) Chromosome 18q allelic loss and prognosis in stage II and III colon cancer. Int J Cancer 79: 390-395.
23. Ogunbiyi OA, Goodfellow PJ, Herfarth K, Gagliardi G, Swanson PE, et al. (1998) Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J Clin Oncol 16: 427-433.
24. Huijsmans R, Damen J, van der Linden H, Hermans M, (2007) Single nucleotide polymorphism profiling assay to confirm the identity of human tissues. J Mol Diagn 9: 205-213.